The FDA has nailed an Australian contract manufacturer with a warning letter for serious manufacturing and quality lapses after banning the company’s products in the fall. More: FDA issues warning letter to Australian CMO Source: fierce
read moreA late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed. More: Cabometyx trial halted early on success in liver cancer Source: News
read moreCDMO Cambrex has decided to be an early adopter of continuous flow manufacturing, installing the technology at a site in Sweden where it will make intermediates for AstraZeneca. More: Cambrex adds continuous manufacturing to sites in U.S. and Europe Source:
read moreAs GlaxoSmithKline CEO Emma Walmsley continues to mold the company into something she says will be more competitive, she is changing the way it markets in emerging markets. For sub-Saharan Africa, that will mean relying on distributors, a move that
read morePfizer is facing tough ALK-positive lung-cancer competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making it any easier for the company to branch out. More: NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF
read moreValeant and Pershing Square are one step closer to putting years of insider trading allegations in the past. More: Judge signals early support for Valeant settlement, company says Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals